A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4

被引:95
作者
Lu Gaohua [2 ]
Abduljalil, Khaled [2 ]
Jamei, Masoud [2 ]
Johnson, Trevor N. [2 ]
Rostami-Hodjegan, Amin [1 ,2 ]
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PT, Lancs, England
[2] Simcyp Ltd, Sheffield, S Yorkshire, England
关键词
caffeine; metoprolol; midazolam; physiologically based pharmacokinetic model; pregnancy; BLOOD-BRAIN-BARRIER; TISSUE DISTRIBUTION; COMPUTER-MODEL; CAFFEINE; WOMEN; TRANSPORTERS; METOPROLOL; POSTPARTUM; SIMULATION; MIDAZOLAM;
D O I
10.1111/j.1365-2125.2012.04363.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Pregnant women are usually not part of the traditional drug development programme. Pregnancy is associated with major biological and physiological changes that alter the pharmacokinetics (PK) of drugs. Prediction of the changes to drug exposure in this group of patients may help to prevent under- or overtreatment. We have used a pregnancy physiologically based pharmacokinetic (p-PBPK) model to assess the likely impact of pregnancy on three model compounds, namely caffeine, metoprolol and midazolam, based on the knowledge of their disposition in nonpregnant women and information from in vitro studies. Methods A perfusion-limited form of a 13-compartment full-PBPK model (Simcyp (R) Simulator) was used for the nonpregnant women, and this was extended to the pregnant state by applying known changes to all model components (including the gestational related activity of specific cytochrome P450 enzymes) and through the addition of an extra compartment to represent the fetoplacental unit. The uterus and the mammary glands were grouped into the muscle compartment. The model was implemented in Matlab Simulink and validated using clinical observations. Results The p-PBPK model predicted the PK changes of three model compounds (namely caffeine, metoprolol and midazolam) for CYP1A2, CYP2D6 and CYP3A4 during pregnancy within twofold of observed values. The changes during the third trimester were predicted to be a 100% increase, a 30% decrease and a 35% decrease in the exposure of caffeine, metoprolol and midazolam, respectively, compared with the nonpregnant women. Conclusions In the absence of clinical data, the in silico prediction of PK behaviour during pregnancy can provide a valuable aid to dose adjustment in pregnant women. The performance of the model for drugs metabolized by a single enzyme to different degrees (high and low extraction) and for drugs that are eliminated by several different routes warrants further study.
引用
收藏
页码:873 / 885
页数:13
相关论文
共 52 条
  • [1] Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal PregnancyA Database for Parameters Required in Physiologically Based Pharmacokinetic Modelling
    Khaled Abduljalil
    Penny Furness
    Trevor N. Johnson
    Amin Rostami-Hodjegan
    Hora Soltani
    [J]. Clinical Pharmacokinetics, 2012, 51 (6) : 365 - 396
  • [2] ALDRIDGE A, 1981, SEMIN PERINATOL, V5, P310
  • [3] Ambrosi G, 1995, ITALIAN JOURNAL OF ANATOMY AND EMBRYOLOGY, VOL 100 - SUPPLEMENT N.1 - 1995, P177
  • [4] Pregnancy-induced changes in pharmacokinetics - A mechanistic-based approach
    Anderson, GD
    [J]. CLINICAL PHARMACOKINETICS, 2005, 44 (10) : 989 - 1008
  • [5] Andrew MA, 2010, BERL POP APPR GROUP
  • [6] Physiologically Based Pharmacokinetic Model of Midazolam Disposition during Pregnancy
    Andrew, Marilee A.
    Hebert, Mary F.
    Vicini, Paolo
    [J]. 2008 30TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1-8, 2008, : 5454 - +
  • [7] [Anonymous], 2004, Guidance for Industry: botanical drug products, P1
  • [8] [Anonymous], 2005, Glossary of terms related to patient and medication safety, P1
  • [9] PHARMACOKINETICS OF CAFFEINE DURING AND AFTER PREGNANCY
    BRAZIER, JL
    RITTER, J
    BERLAND, M
    KHENFER, D
    FAUCON, G
    [J]. DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1983, 6 (05): : 315 - 322
  • [10] Center for Drug Evaluation Research, 2002, GUID PREV INTR CATH, P1